RxDoctor Payments Data

Brandon Jensen, DO

Internal Medicine · Henderson, NVNPI 1821476797

Payments from drug & device makers

$10,420in general payments, 2019–2025

Across 462 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$1K
  • Pfizer$878
  • Novo Nordisk$770
  • Amgen$675
  • AbbVie$485
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$474
  • plus $6K from 38 others

What the payments were for

  • Food & beverage$10,36199%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,420 in reported general payments places this provider in the 90th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$165,602
Medicare patients
182
Services billed
6,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$69,243
EliquisApixaban41$46,961
JardianceEmpagliflozin17$19,565
Repatha SureclickEvolocumab19$13,643
MounjaroTirzepatide12$11,969
Aimovig AutoinjectorErenumab-Aooe11$9,624
Abiraterone Acetate12$8,071
LinzessLinaclotide14$7,342
NexletolBempedoic Acid11$4,195
SynthroidLevothyroxine Sodium20$1,737
Atorvastatin Calcium71$865
Albuterol Sulfate HfaAlbuterol Sulfate24$698
Levothyroxine Sodium70$697
Tamsulosin Hcl36$660
Losartan Potassium67$606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$770$69,24360 claims
PfizerEliquis$878$46,96141 claims
Boehringer IngelheimJardiance$342$19,56517 claims
Lilly USA, LLCMounjaro$265$11,96912 claims
AbbVieLinzess, Synthroid$485$9,07934 claims
Esperion Therapeutics, Inc.Nexletol$238$4,19511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →